CredoScientia - Bibliothèque

Pathologic complete response to conversion therapy in hepatocellular carcinoma using patient-derived organoids: A case report.

BACKGROUND: For primary liver cancer, the key to conversion therapy depends on the effectiveness of drug treatment. Patient-derived tumor organoids have been demonstrated to improve the efficacy of co…

Thérapies de Conversion

He, Y. G., Wang, Z., Li, J., Xi, W., Zhao, C. Y., Huang, X. B., & Zheng, L. (2024). Pathologic complete response to conversion therapy in hepatocellular carcinoma using patient-derived organoids: A case report.. World J Gastrointest Oncol, 16(11), 4506-4513. https://doi.org/10.4251/wjgo.v16.i11.4506

15/11/2024 Lire →

Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial.

PURPOSE: This phase II trial investigated the safety and efficacy of chemoradiotherapy (CRT) followed by immunochemotherapy (iCT) and surgery in unresectable locally advanced esophageal squamous cell …

Thérapies de Conversion

Wang, X., Kang, X., Zhang, R., Xue, L., Xu, J., Zhao, X., Ou, Q., Yu, N., Feng, G., Li, J., Zheng, Z., Chen, X., Wang, Z., Zheng, Q., Li, Y., Qin, J., Bi, N., & Li, Y. (2024). Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial.. Clin Cancer Res, 30(22), 5061-5072. https://doi.org/10.1158/1078-0432.CCR-24-1236

15/11/2024 Lire →

Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients.

Thérapies de Conversion

Gorgulho, J., & von, F. e. l. d. e. n. . J. (2024). Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients.. Aliment Pharmacol Ther, 60(10), 1467-1468. https://doi.org/10.1111/apt.18296

01/11/2024 Lire →

The Umbilical.

Traditional psychoanalytic approaches view excessive parental, social or relational involvement in human development as an opportunity for linking complex gender and identity experiences. The analyst'…

Thérapies de Conversion

Barlow, J. (2024). The Umbilical.. J Anal Psychol, 69(5), 827-854. https://doi.org/10.1111/1468-5922.13044

01/11/2024 Lire →

Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients. Author

Thérapies de Conversion

Hatanaka, T., Kakizaki, S., Hiraoka, A., Tada, T., & Kumada, T. (2024). Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients. Author. Aliment Pharmacol Ther, 60(10), 1469-1470. https://doi.org/10.1111/apt.18319

01/11/2024 Lire →

[Expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma(2024 edition)].

Up to half of hepatocellular carcinoma(HCC) cases are diagnosed at an advanced stage,for which effective treatment options are lacking,resulting in a poor prognosis. In recent years,the combination of…

Thérapies de Conversion

Professional, C. o. m. m. i. t. t. e. e. . f. o. r. . P. r. e. v. e. n. t. i. o. n. . a. n. d. . C. o. n. t. r. o. l. . o. f. . H. e. p. a. t. o. b. i. l. i. a. r. y. . a. n. d. . P. a. n. c. r. e. a. t. i. c. . D. i. s. e. a. s. e. s. . o. f. . C. h. i. n. e. s. e. . P. r. e. v. e. n. t. i. v. e. . M. e. d. i. c. i. n. e. . A. s. s. o. c. i. a. t. i. o. n., Chinese, S. o. c. i. e. t. y. . o. f. . L. i. v. e. r. . C. a. n. c. e. r., & Liver, S. t. u. d. y. . G. r. o. u. p. . o. f. . S. u. r. g. e. r. y. . C. o. m. m. i. t. t. e. e. . o. f. . B. e. i. j. i. n. g. . M. e. d. i. c. a. l. . A. s. s. o. c. i. a. t. i. o. n. (2024). [Expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma(2024 edition)].. Zhonghua Wai Ke Za Zhi, 62(11), 984-995. https://doi.org/10.3760/cma.j.cn112139-20240814-00245

01/11/2024 Lire →

Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients.

AIM: This study aims to investigate the predictive factors for conversion therapy in patients with unresectable hepatocellular carcinoma (uHCC) and to evaluate the prognosis of conversion cases by com…

Thérapies de Conversion

Hatanaka, T., Kakizaki, S., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., Tsuji, K., Ishikawa, T., Tajiri, K., Toyoda, H., Ogawa, C., Nishikawa, H., Nishimura, T., Kawata, K., … Real‐life, P. r. a. c. t. i. c. e. . E. x. p. e. r. t. s. . f. o. r. ,. . H. C. C. . (. R. E. L. P. E. C. ). . S. t. u. d. y. . G. r. o. u. p. ,. . a. n. d. ,. . H. C. C. . 4. 8. . G. r. o. u. p. . (. H. e. p. a. t. o. c. e. l. l. u. l. a. r. . C. a. r. c. i. n. o. m. a. . E. x. p. e. r. t. s. . f. r. o. m. . 4. 8. . C. l. i. n. i. c. s. . i. n. . J. a. p. a. n. ). (2024). Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients.. Aliment Pharmacol Ther, 60(10), 1361-1373. https://doi.org/10.1111/apt.18237

01/11/2024 Lire →

Estimating Efficacy of Conversion Therapy on Patients with Initially Unresectable Colorectal Cancer Liver Metastases by using MRI: Development of a Predictive Score.

RATIONALE AND OBJECTIVES: The conversion success rate (CSR) has crucial implication for clinical outcomes of initially unresectable colorectal liver metastases (CRLM) following conversion therapy. Thi…

Thérapies de Conversion

Liu, J., Tang, W., Ye, L., Miao, G., Zeng, M., & Liu, L. (2024). Estimating Efficacy of Conversion Therapy on Patients with Initially Unresectable Colorectal Cancer Liver Metastases by using MRI: Development of a Predictive Score.. Acad Radiol, 31(11), 4478-4487. https://doi.org/10.1016/j.acra.2024.04.038

01/11/2024 Lire →

Immune Checkpoint Inhibitors in the Pre-Transplant Hepatocellular Carcinoma Setting: A Glimpse Beyond the Liver.

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the third leading cause of cancer-related death worldwide. Liver transplantation (LT) is the best therapy for most patients w…

Thérapies de Conversion

Marzi, L., Mega, A., Turri, C., Gitto, S., Ferro, F., & Spizzo, G. (2024). Immune Checkpoint Inhibitors in the Pre-Transplant Hepatocellular Carcinoma Setting: A Glimpse Beyond the Liver.. Int J Mol Sci, 25(21). https://doi.org/10.3390/ijms252111676

30/10/2024 Lire →

Reassessment of palliative surgery in conversion therapy of previously unresectable hepatocellular carcinoma: Two case reports and review of literature.

BACKGROUND: Most patients with hepatocellular carcinoma (HCC) have lost the opportunity for direct surgery at the time of diagnosis. Transarterial chemoembolization (TACE) combined with immune checkpo…

Thérapies de Conversion

Zhu, Y. B., Qin, J. Y., Zhang, T. T., Zhang, W. J., & Ling, Q. (2024). Reassessment of palliative surgery in conversion therapy of previously unresectable hepatocellular carcinoma: Two case reports and review of literature.. World J Gastrointest Surg, 16(10), 3312-3320. https://doi.org/10.4240/wjgs.v16.i10.3312

27/10/2024 Lire →

Clinical study on conversion therapy of hepatocellular carcinoma - summary and comparison of clinical data from a single center of consecutive four years.

AIM: The purpose of this study was to interpret real-world clinical data to analyze the surgical safety and survival outcomes of patients with initial unresectable hepatocellular carcinoma (uHCC) afte…

Thérapies de Conversion

Chang, Z., Li, M., Sun, Z., Liu, Z., Yang, Y., Xu, L., Li, L., Zhang, C., Sun, P., Zhong, J., Zhang, B., Shi, X., Cui, K., Zhang, J., Li, Z., & Zhao, L. (2024). Clinical study on conversion therapy of hepatocellular carcinoma - summary and comparison of clinical data from a single center of consecutive four years.. BMC Gastroenterol, 24(1), 369. https://doi.org/10.1186/s12876-024-03457-8

17/10/2024 Lire →

Conversion therapy for unresectable hepatocellular carcinoma: Advances and challenges.

Recently, the published an article entitled "Pathologically successful conversion hepatectomy for advanced giant hepatocellular carcinoma after multidisciplinary therapy: A case report and review of …

Thérapies de Conversion

He, Y. F. (2024). Conversion therapy for unresectable hepatocellular carcinoma: Advances and challenges.. World J Gastrointest Oncol, 16(10), 4289-4297. https://doi.org/10.4251/wjgo.v16.i10.4289

15/10/2024 Lire →